Breaking News
December 13, 2018 - Drug repositioning strategy identifies potential new treatments for epilepsy
December 13, 2018 - Chronic rhinitis associated with hospital readmissions for asthma and COPD patients
December 13, 2018 - Food poisoning discovery could save lives
December 13, 2018 - Cloned antibodies show potential to treat, diagnose life-threatening fungal infections
December 13, 2018 - Exercise may reduce colorectal cancer risk after weight loss
December 13, 2018 - Russian scientists create hardware-information system for brain disorders treatment
December 13, 2018 - Moderate alcohol consumption linked with lower risk of hospitalization
December 13, 2018 - Nurturing Healthy Neighborhoods | NIH News in Health
December 13, 2018 - Rise in meth and opioid use during pregnancy
December 13, 2018 - Researchers gain new insights into pediatric tumors
December 13, 2018 - FSU study finds racial disparity among adolescents receiving flu vaccine
December 13, 2018 - Drug cocktail induces cancer cell death by switching off energy supply
December 13, 2018 - Baculovirus virion completely eliminates liver-stage parasites in mouse model
December 13, 2018 - Researchers create noninvasive technology that detects when nerve cells fire
December 13, 2018 - Treating patients with hypertension induced albuminuria
December 13, 2018 - New substance could improve efficacy of established breast cancer treatments
December 13, 2018 - Scientists develop new stem cell line to study conversion of stem cells into muscle
December 13, 2018 - Re-programming the body’s energy pathway boosts kidney self-repair
December 13, 2018 - Research findings could help improve treatment of anxiety and post-traumatic stress disorders
December 13, 2018 - The Microbiome Movement announce Microbiotica as official industry partner
December 13, 2018 - New study reveals potential benefits of cEEG monitoring for infant ICU patients
December 13, 2018 - Whole-body imaging PET/MRI offers information to guide treatment options for prostate cancer
December 13, 2018 - International investigators fight against the negative campaign on benzodiazepines
December 13, 2018 - Targeting biochemical pathway may lead to new therapies for alleviating symptoms of anxiety disorders
December 13, 2018 - FDA Approves Tolsura (SUBA®-itraconazole capsules) for the Treatment of Certain Fungal Infections
December 13, 2018 - Are scientists studying the wrong kind of mice?
December 13, 2018 - Computer memory: A scientific team builds a virtual model of a key brain region
December 13, 2018 - Visual inspection alone is insufficient to diagnose skin cancer
December 13, 2018 - Paternal grandfather’s access to food associated with grandson’s mortality risk
December 13, 2018 - Our brain senses angry voices in a flash, study shows
December 13, 2018 - PM2.5 Exposure Linked to Asthma Rescue Medication Use
December 13, 2018 - Can’t exercise? A hot bath may help improve inflammation, metabolism, study suggests
December 13, 2018 - Can artificial intelligence help doctors with the human side of medicine?
December 13, 2018 - Virginia Tech and UC San Diego researchers team up to develop nonopioid drug for chronic pain
December 13, 2018 - NIH offers support for HIV care and prevention research in the southern United States
December 12, 2018 - Activating brain region could revive the urge to socialize among opioid addicts
December 12, 2018 - Relationship impairment appears to interfere with seeking mental health treatment in men
December 12, 2018 - Sleep, Don’t Cram, Before Finals for Better Grades
December 12, 2018 - Effective treatments for urticarial vasculitis
December 12, 2018 - Gun violence is a public health issue: One physician’s story
December 12, 2018 - The Science of Healthy Aging
December 12, 2018 - Yes to yoghurt and cheese: New improved Mediterranean diet
December 12, 2018 - Researchers uncover a number of previously unknown insecticide resistance mechanisms
December 12, 2018 - Regulating the immune system’s ‘regulator’
December 12, 2018 - In breaking bad news, the comfort of silence
December 12, 2018 - Study finds upward link between alcohol consumption and physical activity in college students
December 12, 2018 - FDA issues warning letter to Zhejiang Huahai Pharmaceutical involved in valsartan recall
December 12, 2018 - Weight history at ages 20 and 40 could help predict patients’ future risk of heart failure
December 12, 2018 - Presence of antiphospholipid antibodies tied to first-time MI
December 12, 2018 - DNA analysis finds that stethoscopes are teaming with bacteria
December 12, 2018 - New study could help inform research on preventing falls
December 12, 2018 - Women and men with heart attack symptoms receive different care from EMS
December 12, 2018 - Disrupted biological clock can contribute to onset of diseases, USC study shows
December 12, 2018 - New publications generate controversy over the value of reducing salt consumption in populations
December 12, 2018 - New data from TAILORx trial confirms lack of chemo benefit regardless of race or ethnicity
December 12, 2018 - Specific class of biomarkers can accurately indicate the severity of cancer
December 12, 2018 - Meds Taken Do Not Vary With ADL Impairment in Heart Failure
December 12, 2018 - Long-term study shows that HIV-2 is deadlier than previously thought
December 12, 2018 - People living near oil and gas wells show early signs of cardiovascular disease
December 12, 2018 - IONTAS founder and pioneer in phage display technology attends Nobel Prize Award Ceremony
December 12, 2018 - People who eat red meat have high levels of chemical associated with heart disease, study finds
December 12, 2018 - New method uses water molecules to unlock neurons’ secrets
December 12, 2018 - Genetics study offers hope for new acne treatment
December 12, 2018 - New computer model predicts prostate cancer progression
December 12, 2018 - Nobel Laureates lecture about immune checkpoint therapy for cancer treatment
December 12, 2018 - More Illnesses From Tainted Romaine Lettuce Reported
December 12, 2018 - Aspirin could reduce HIV infections in women
December 12, 2018 - The EORTC Brain Tumor Group and Protagen AG collaborate to study immuno-competence of long-term glioblastoma survivors
December 12, 2018 - Insights into magnetotactic bacteria could guide development of biological nanorobots
December 12, 2018 - Sacrificial immune cells alert body to infection
December 12, 2018 - Low-salt diet may be more beneficial for females than males
December 12, 2018 - Major soil organic matter compound battles chronic wasting disease
December 12, 2018 - Findings may open up new ways to treat dwarfism and other ER-stress-related conditions
December 12, 2018 - New computational model provides clearer picture of shape-changing cells’ structure and mechanics
December 12, 2018 - 10 Facts on Patient Safety
December 12, 2018 - Poorest dying nearly 10 years younger than the rich in ‘deeply worrying’ trend for UK
December 12, 2018 - Innovative care model for children with ASD reduces use of behavioral drugs in ED
December 12, 2018 - Spending time in and around Hong Kong’s waters linked to better health and wellbeing
December 12, 2018 - Simple measures to prevent weight gain over Christmas
December 12, 2018 - Research advances offer hope for patient-tailored AML treatment
A Tribute to Dr. Ray Lipicky: The Man Who Transformed Cardiology

A Tribute to Dr. Ray Lipicky: The Man Who Transformed Cardiology

image_pdfDownload PDFimage_print

Most cardiologists assume that the way we currently think about things in cardiology has always been part of our DNA. We are strongly evidence-based, and we are skeptical of mechanisms that have no supporting data. We recognize the limitation of small trials, and we understand how missing data creates bias. We know that rigorous clinical trials are the only way to inform our use of drugs.

Has cardiology always been this way? Actually, no.

Forty years ago, thinking in cardiology was dominated by wonderful story-telling, but without much evidence. Trials were small, and many were not well designed or executed. They often focused on things that we thought were important, based on our beliefs about a disease. We knew that shortcuts commonly gave the wrong answer, but we embraced them because we did not know better.

One man made all the difference: Dr. Raymond Lipicky.

Ray led the FDA Division of Cardiac and Renal Drug Products from 1981-2002. During those 21 years, his unique intellect and way of thinking transformed the cardiovascular drug evaluation and approval process. Too slowly, his approach to cardiovascular drugs is now being adopted in other therapeutic areas.

What was special about Ray Lipicky? Each of us would probably answer that question a bit differently, as would hundreds of others whom he influenced. But in essence, it all came down to a single summary statement.

He taught us how to challenge the casual assumptions that kept getting in the way of progress.

Ray didn’t provide us with a formula as to how to think. Instead, he was exceptional at challenging our basic thought processes. If we assumed something was true, Ray wanted to know why. If we assumed that there was one way to do something, Ray might suggest three other ways.

His favorite reply: “Why do you think that?”

Many of us who were on the receiving end of that question were often stunned by it. There would be a long moment of silence, often with our jaws wide open. Ray would notice the lack of a response, and he would chuckle.

Ray had a unique chuckle. It was never condescending or judgmental; it was never intended to create discomfort. Its entire purpose was to help the listener move to a new way of thinking. The chuckle gave us permission to laugh at ourselves. When we heard the chuckle, we knew it was time to start paying attention.

Ray always asked the really tough questions. How do you know that ventricular premature beats are bad? How do you know that clots in the coronary arteries are important? How do you know that positive inotropic agents are good for the heart?

He didn’t ask these questions because he thought we would come up with answers. He asked because he wanted us to wonder whether the assumptions we had in our heads were actually true. And he pushed us to come up with a way to test our theories using logic and empirical evidence.

The four of us interacted with Ray in different ways during his tenure at FDA and beyond. Three of us were employed at FDA at various times. But Ray’s influence was felt throughout the academic cardiology community, and it was felt in every sector that was interested in cardiovascular drug development.

In the 1980s and 1990s, if you wanted to learn how to think about therapeutics, all you needed to do was to attend a public meeting of the FDA’s Cardiac and Renal Drugs Advisory Committee. In those days, the meetings discussed the pros and cons of over a dozen new chemical entities each year. At each meeting, the members of the committee typically sat along a linear table in front of an audience that was packed with hundreds of people. Ray Lipicky was at one end of the table, and Dr. Robert Temple (who had preceded Ray as Division Director) was at the other. When they had a discussion or a disagreement, you could hear some amazing intellectual discourse. For all of us, those debates opened our minds and our hearts.

Dr. Ray Lipicky passed away last week.

For everyone who works in the field of cardiology today, the loss is profound. For those of us who knew him, worked with him, learned from him, and were transformed by him, the world is suddenly left without the person who had made such a difference.

Why do we think that? Even though we can no longer hear Ray say those exact words, we will always remember them — and him.

Milton Packer

Robert M. Califf

Norman Stockbridge

Robert R. Fenichel

Packer recently consulted for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi Sankyo, Gilead, Novo Nordisk, Relypsa, Sanofi, Takeda, and ZS Pharma. He chairs the EMPEROR Executive Committee for trials of empagliflozin for the treatment of heart failure. He was previously the co-PI of the PARADIGM-HF trial and serves on the Steering Committee of the PARAGON-HF trial, but has no financial relationship with Novartis.

1969-12-31T19:00:00-0500

last updated

Tagged with:

About author

Related Articles